|
Panel Calls for Swift FDA Approval of Lucentis for Diabetic ME
A panel of FDA advisors called for swift approval of Genentech’s sBLA for Lucentis to treat diabetic macular edema (DME), saying the drug’s efficacy and safety profile far outweigh any statistical shortcomings.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives